2.1 Study participants
415 patients (age 18-65 years) with HDM-induced AR with or without asthma were recruited from 71 general practices or outpatient clinics of allergologists, dermatologists, Ear-Nose-Throat (ENT) specialists or pulmonologists in the Netherlands between September 2017 and March 2019. A patient was diagnosed with HDM allergy, when having a positive skin prick test to HDM extract or allergen specific HDM IgE level of ³ 0.35 IU/mL next to an appropriate clinical history. The decision to initiate treatment with HDM SLIT-tablet was made at the discretion of the physician. Key discontinuation criteria were patient-based decision or treatment-related adverse event (AE). The study was approved by the Dutch Clinical Research Federation/nWMO Advisory Committee Twente (no. NWMO17.04.017) and the applicable ethics committees and institutional review boards. All patients gave written informed consent. The study complies with the Declaration of Helsinki.